CytoKinetics is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing novel muscle activators and inhibitors for the treatment of diseases of impaired muscle function. The company's vision is "empowering muscle, empowering lives" with a focus on cardiac and skeletal muscle disorders[@cytokinetics].
Pipeline Overview
| Program | Target/Mechanism | Indication | Stage | Status | |---------|-----------------|------------|-------|--------| | Aficamten (CK-037825) | Cardiac myosin inhibitor | Hypertrophic cardiomyopathy | Approved | MYQORZO™ | | Reldesomstat (CK-2127107) | Fast skeletal muscle troponin inhibitor | ALS | Phase 3 | Clinical | | CK-089 | Fast skeletal muscle troponin activator | Neuromuscular | Phase 1 | Active |
Corporate History
1998: Operations began in South San Francisco
2004: Completed initial public offering (NASDAQ: CYTK)
2008: Strategic realignment focused on muscle biology
2018: Began Phase 1 study of cardiac myosin inhibitor
2023: Announced results from SEQUOIA-HCM Phase 3 trial
2024: FDA accepted New Drug Application for aficamten
2025: Received first FDA approval for MYQORZO™ (aficamten) for obstructive HCM
Strategic Partnerships
CytoKinetics has established strategic partnerships with major pharmaceutical companies:
Astellas Pharma: Collaboration on fast skeletal muscle activators
Amgen: Option agreement for cardiac myosin inhibitor program
Royalty Pharma: Royalty financing arrangement
...
CytoKinetics
Overview
CytoKinetics is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing novel muscle activators and inhibitors for the treatment of diseases of impaired muscle function. The company's vision is "empowering muscle, empowering lives" with a focus on cardiac and skeletal muscle disorders[@cytokinetics].
Pipeline Overview
| Program | Target/Mechanism | Indication | Stage | Status | |---------|-----------------|------------|-------|--------| | Aficamten (CK-037825) | Cardiac myosin inhibitor | Hypertrophic cardiomyopathy | Approved | MYQORZO™ | | Reldesomstat (CK-2127107) | Fast skeletal muscle troponin inhibitor | als | Phase 3 | Clinical | | CK-089 | Fast skeletal muscle troponin activator | Neuromuscular | Phase 1 | Active |
Corporate History
1998: Operations began in South San Francisco
2004: Completed initial public offering (NASDAQ: CYTK)
2008: Strategic realignment focused on muscle biology
2018: Began Phase 1 study of cardiac myosin inhibitor
2023: Announced results from SEQUOIA-HCM Phase 3 trial
2024: FDA accepted New Drug Application for aficamten
2025: Received first FDA approval for MYQORZO™ (aficamten) for obstructive HCM
Strategic Partnerships
CytoKinetics has established strategic partnerships with major pharmaceutical companies:
Astellas Pharma: Collaboration on fast skeletal muscle activators
Amgen: Option agreement for cardiac myosin inhibitor program
Royalty Pharma: Royalty financing arrangement
Financial Information
Stock Ticker: CYTK (NASDAQ)
The company has maintained a strong financial position with ongoing clinical trials and recent FDA approval providing commercial revenue potential.
Neurological Relevance
While primarily focused on cardiac and skeletal muscle disorders, CytoKinetics has relevance to neurodegenerative disease research through:
ALS Program (Reldesomstat)
The company's Phase 3 program in amyotrophic lateral sclerosis (ALS) targets muscle function:
Fast skeletal muscle troponin inhibitor
Aims to improve muscle strength and function in ALS patients
Addresses the muscle weakness component of ALS pathology
neurodegeneration" style="color:#e0e0e0;margin:1.2rem 0 0.5rem;font-size:1rem;font-weight:600;border-bottom:1px solid rgba(255,255,255,0.08);padding-bottom:0.3rem">Connection to Neurodegeneration
Muscle dysfunction is a significant component of several neurodegenerative diseases:
[ALS](/diseases/amyotrophic-lateral-sclerosis) affects motor [neurons](/entities/neurons) leading to muscle weakness